Thalys Medical Technology Group Past Earnings Performance
Past criteria checks 0/6
Thalys Medical Technology Group's earnings have been declining at an average annual rate of -68.8%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
-68.8%
Earnings growth rate
-69.9%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | 6.2% |
Return on equity | -10.3% |
Net Margin | -6.9% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Thalys Medical Technology Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 2,047 | -141 | 341 | 45 |
31 Dec 23 | 2,006 | -159 | 356 | 43 |
30 Sep 23 | 2,076 | -153 | 364 | 40 |
30 Jun 23 | 2,170 | -154 | 389 | 32 |
31 Mar 23 | 2,174 | -190 | 426 | 28 |
31 Dec 22 | 2,309 | -154 | 424 | 29 |
30 Sep 22 | 2,536 | -55 | 425 | 26 |
30 Jun 22 | 2,552 | -51 | 427 | 31 |
31 Mar 22 | 2,662 | -33 | 410 | 34 |
31 Dec 21 | 2,600 | -50 | 400 | 35 |
30 Sep 21 | 2,595 | 30 | 322 | 38 |
30 Jun 21 | 2,552 | 53 | 303 | 34 |
31 Mar 21 | 2,361 | 88 | 286 | 28 |
31 Dec 20 | 2,125 | 58 | 283 | 19 |
30 Sep 20 | 1,878 | 50 | 304 | 10 |
30 Jun 20 | 1,761 | 62 | 289 | 9 |
31 Mar 20 | 1,752 | 64 | 283 | 9 |
31 Dec 19 | 1,831 | 110 | 272 | 11 |
30 Sep 19 | 1,699 | 112 | 265 | 11 |
30 Jun 19 | 1,585 | 102 | 247 | 10 |
31 Mar 19 | 1,417 | 97 | 230 | 8 |
31 Dec 18 | 1,317 | 94 | 215 | 7 |
30 Sep 18 | 1,231 | 110 | 200 | 6 |
30 Jun 18 | 1,135 | 105 | 191 | 8 |
31 Mar 18 | 1,018 | 98 | 171 | 7 |
31 Dec 17 | 921 | 94 | 160 | 5 |
30 Sep 17 | 787 | 74 | 138 | 4 |
30 Jun 17 | 694 | 70 | 123 | 0 |
31 Mar 17 | 652 | 73 | 115 | 0 |
31 Dec 16 | 627 | 69 | 111 | 0 |
30 Sep 16 | 600 | 69 | 99 | 0 |
31 Dec 15 | 530 | 61 | 92 | 0 |
31 Dec 14 | 445 | 57 | 79 | 0 |
31 Dec 13 | 392 | 49 | 71 | 0 |
Quality Earnings: 603716 is currently unprofitable.
Growing Profit Margin: 603716 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603716 is unprofitable, and losses have increased over the past 5 years at a rate of 68.8% per year.
Accelerating Growth: Unable to compare 603716's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 603716 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 603716 has a negative Return on Equity (-10.31%), as it is currently unprofitable.